Literature DB >> 25003362

Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications.

M K S Leow1, R Dalan2, C B E Chee3, A Earnest4, D E K Chew2, A W K Tan2, W Y C Kon1, M Jong1, T Barkham5, Y T Wang3.   

Abstract

BACKGROUND: Diabetes mellitus (DM) confers a higher risk for tuberculosis (TB). Yet, TB screening and chemoprophylaxis for latent TB infection (LTBI) in DM remains controversial. We conducted a cross-sectional study to elucidate LTBI prevalence and longitudinal follow-up to ascertain LTBI to active TB progression rate in DM.
METHODS: 220 DM patients without previous TB from the outpatient diabetes clinic of the hospital were enrolled. T-Spot TB, tuberculin-skin-test (TST) and chest radiography (CXR) were performed. LTBI was defined by negative CXR with reactive T-Spot TB. Progression to active TB was confirmed by cross-checking against the TB registry.
RESULTS: The prevalence of LTBI was 28.2% (62/220) by reactive T-Spot. None progressed to active TB from 2007-2013. Multivariate analysis revealed that any co-morbidity (p=0.016) was positively associated while metformin (p=0.008) was negatively associated with LTBI.
CONCLUSIONS: Over a quarter of DM patients harbor LTBI. While the lack of demonstrable progression to active TB within the follow-up time frame up to this point does not unequivocally support a routine TB screening policy or anti-TB chemoprophylaxis for LTBI in a diabetic population for now, this preliminary evidence needs re-evaluation with longer follow-up of this enrolled cohort over the next decade. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 25003362     DOI: 10.1055/s-0034-1377044

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  12 in total

1.  Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus.

Authors:  R L Hensel; R R Kempker; J Tapia; A Oladele; H M Blumberg; M J Magee
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

2.  Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins.

Authors:  Matthew J Magee; Argita D Salindri; Hardy Kornfeld; Amit Singhal
Journal:  Eur Respir J       Date:  2019-03-14       Impact factor: 16.671

3.  Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis.

Authors:  Meng Zhang; Jian-Qing He
Journal:  Eur J Clin Pharmacol       Date:  2019-11-30       Impact factor: 2.953

4.  Negative latent tuberculosis at time of incarceration: identifying a very high-risk group for infection.

Authors:  L Arroyave; Y Keynan; L López; D Marin; M P Arbeláez; Z V Rueda
Journal:  Epidemiol Infect       Date:  2017-07-31       Impact factor: 4.434

Review 5.  Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?

Authors:  Chunlan Zheng; Xiufen Hu; Li Zhao; Minhui Hu; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2017-10-11       Impact factor: 4.162

6.  HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients.

Authors:  Ken Tashiro; Nobuyuki Horita; Kenjiro Nagai; Misako Ikeda; Masaharu Shinkai; Masaki Yamamoto; Takashi Sato; Yu Hara; Hideyuki Nagakura; Yuji Shibata; Hiroki Watanabe; Kentaro Nakashima; Ryota Ushio; Akimichi Nagashima; Atsuya Narita; Nobuaki Kobayashi; Makoto Kudo; Takeshi Kaneko
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

7.  Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects.

Authors:  Ekta Lachmandas; Clare Eckold; Julia Böhme; Valerie A C M Koeken; Mardiana Binte Marzuki; Bastiaan Blok; Rob J W Arts; Jinmiao Chen; Karen W W Teng; Jacqueline Ratter; Elise J Smolders; Corina Van den Heuvel; Rinke Stienstra; Hazel M Dockrell; Evan Newell; Mihai G Netea; Amit Singhal; Jacqueline M Cliff; Reinout Van Crevel
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

8.  Prevalence and Risk Factors of Latent Tuberculosis Infection (LTBI) in Patients with Type 2 Diabetes Mellitus (T2DM).

Authors:  Phan Ai Ping; Rosnani Zakaria; Md Asiful Islam; Lili Husniati Yaacob; Rosediani Muhamad; Wan Mohamad Zahiruddin Wan Mohamad; Harmy Mohamed Yusoff
Journal:  Int J Environ Res Public Health       Date:  2021-01-04       Impact factor: 3.390

9.  Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion.

Authors:  Jason D Simmons; Phu T Van; Catherine M Stein; Violet Chihota; Thobani Ntshiqa; Pholo Maenetje; Glenna J Peterson; Anthony Reynolds; Penelope Benchek; Kavindhran Velen; Katherine L Fielding; Alison D Grant; Andrew D Graustein; Felicia K Nguyen; Chetan Seshadri; Raphael Gottardo; Harriet Mayanja-Kizza; Robert S Wallis; Gavin Churchyard; W Henry Boom; Thomas R Hawn
Journal:  J Clin Invest       Date:  2021-07-15       Impact factor: 19.456

10.  Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.

Authors:  Xinyu Yu; Ling Li; Liangtao Xia; Xin Feng; Fan Chen; Shiyi Cao; Xiang Wei
Journal:  BMC Infect Dis       Date:  2019-10-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.